Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights



Results: 1 -10 of 28 Show results per page	View Search Criteria \| Help With Results


1.		Study Comparing Bevacizumab + Temsirolimus Vs Bevacizumab + Interferon-Alfa In Advanced Renal Cell Carcinoma Subjects

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 and over				Pharmaceutical / Industry				3066K1-3311 NCT00631371

Last Modified: 6/16/2008 First Published: 5/23/2005


2.		Phase I/II Study of CCI-779 and Bevacizumab in Patients With Metastatic or Unresectable Renal Cell Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				18 and over				NCI				MAYO-MC0452 NCI-6986, 6986, NCT00112840

Last Modified: 6/7/2007 First Published: 5/23/2005


3.		Phase I/II Study of Erlotinib and Temsirolimus in Patients With Recurrent Malignant Glioma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				18 and over				NCI				NABTC-0402 NCI-06-C-0053, NABTC-04-02, NCT00112736

Last Modified: 9/19/2008 First Published: 5/11/2006


4.		Phase I/II Study of Sorafenib and Temsirolimus in Patients With Recurrent Glioblastoma (Phase I Closed to Accrual as of 11/21/07)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Biomarker/Laboratory analysis, Treatment				Active				18 and over				NCI				NCCTG-N0572 N0572, NCT00329719

Last Modified: 2/21/2007 First Published: 6/2/2006


5.		Phase I/II Study of Sorafenib in Combination With Erlotinib Hydrochloride, Tipifarnib, or Temsirolimus in Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				18 and over				NCI				NABTC-05-02 NABTC-05-02, NCT00335764

Last Modified: 2/21/2007 First Published: 6/23/2006


6.		Phase I/II Study of Sorafenib and Temsirolimus in Patients With Metastatic, Recurrent, or Unresectable Melanoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				18 and over				NCI				MDA-2005-0215 7149, NCI-7149, NCT00349206


7.		Combination CCI-779 (Temsirolimus) and Bortezomib (Velcade) in Relapsed and/or Relapsed/Refractory Multiple Myeloma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				18 and over				Other				06-365 NCT00483262

First Published: 6/16/2008


8.		Phase I/II Study of Anti-IGF-1R Recombinant Monoclonal Antibody IMC-A12 and Temsirolimus in Patients With Locally Recurrent or Metastatic Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Biomarker/Laboratory analysis, Treatment				Approved-not yet active				18 and over				NCI				MAYO-MC0736 8129, MC0736, NCT00699491

Last Modified: 9/16/2008 First Published: 4/23/2005


9.		Phase II Study of CCI-779 and Rituximab in Patients With Relapsed or Refractory Mantle Cell Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				18 and over				NCI				NCCTG-N038H N038H, NCT00109967

Last Modified: 9/17/2008 First Published: 1/20/2006


10.		Phase II Randomized Study of Sorafenib in Combination With Either Temsirolimus or Tipifarnib in Patients With Unresectable Stage IV Malignant Melanoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				18 and over				NCI				SWOG-S0438 S0438, NCT00281957

Select All on One Page


					1 2 3 Next >

| | | | | | | |

A Service of the National Cancer Institute